Aurobindo gets FTC nod for Lannett, moves closing to June
The US regulator clears a key hurdle for the generics deal announced last July. Aurobindo now expects to close before end of June, ahead of initial guidance.
— 6 earlier stories on Aurobindo Pharma Ltd. →What's new
- Aurobindo receives US FTC clearance for Lannett acquisition.
- Closing now expected before end-June, ahead of early Q2 FY27 guidance.
- Deal removes key regulatory hurdle for generics expansion.
Why this matters
The FTC approval de-risks Aurobindo's largest M&A move in years. With two plants under FDA OAI classification, the faster timeline signals confidence in integration. The deal strengthens its US generics presence, but regulatory headwinds at existing facilities remain a drag.
What we're watching
- Integration costs and margin impact from Lannett.
- Lannett's revenue contribution and product pipeline.
- Aurobindo's resolution of OAI designations at its plants.
The full read
Aurobindo Pharma cleared the last big regulatory hurdle for its Lannett acquisition. The US FTC approved the deal, announced in July 2025, and the company now expects to close before end-June — ahead of the early Q2 FY27 guidance. That matters because Aurobindo's US generics business has been under FDA scrutiny; two plants earned OAI designations in the past six months. The acquisition is meant to strengthen that business, but integration costs and ongoing regulatory overhang remain. The FTC nod removes deal uncertainty, but the real test is execution post-close.
Questions answered
- What is the significance of FTC approval for Aurobindo?
- It removes the last major regulatory hurdle for the Lannett acquisition, which was announced in July 2025. Without it, the deal could not close.
- How has the timeline changed?
- Initially expected to close in early Q2 FY27 (July-September 2026), Aurobindo now expects to close before end of June 2026.
- Is the deal size disclosed?
- No, Aurobindo did not disclose financial terms in this filing.
- What does Lannett bring to Aurobindo?
- Lannett is expected to strengthen Aurobindo's presence in the US generics market.
- Has Aurobindo faced any recent regulatory issues?
- Yes, two of its plants received OAI classification from the FDA in the past six months, which could affect its US operations.
Aurobindo Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AUROPHARMA →- 19 Jun 2026 · 8:25 AM IST Aurobindo gets FTC nod for Lannett, moves closing to June
- 6d ago Aurobindo gets second OAI plant in six months
- 28d ago Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year
- 28d ago Aurobindo’s FY26 audited results are a formality. Profit growth is 0.6%.
- 28d ago Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M